Finanzen von MoonLake Immunotherapeutics (MLTX)MLTXMoonLake Immunotherapeutics

Evaluating the bottom line, MoonLake Immunotherapeutics maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -67.44%, provide a clear picture of how effectively MLTX converts its operational activities into shareholder value.

In the context of the broader market, MLTX competes directly with industry leaders such as ALMS and CRVS. With a market capitalization of $1.01B, it holds a leading position in the sector. When comparing efficiency, MLTX's gross margin of N/A stands against ALMS's 100.00% and CRVS's N/A. Such benchmarking helps identify whether MoonLake Immunotherapeutics is trading at a premium or discount relative to its financial performance.

MoonLake reported a narrower Q2 loss of $0.84 per share, which was better than the expected loss of $0.93, showing improved financial management. The company also ended Q2 with a strong cash position of $537 million, which is expected to fund operations into mid-2028, supporting its clinical trials and regulatory submissions.